AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
dexamethasone valerate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 829 | 33755-46-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 0.08 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 81 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.149 | Moderate | 0.77 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.074 | Moderate | 0.77 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 72.946 | 10^-6 cm/s | Moderate | 0.77 |
| dh-clint | Dog hepatocyte intrinsic clearance | 17.947 | uL/min/10^6 cells | Moderate | 0.77 |
| dppb | Dog plasma protein binding (% unbound) | 5.020 | % | Moderate | 0.77 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 9.760 | % | Moderate | 0.77 |
| herg | hERG pIC50 | 4.649 | pIC50 | Moderate | 0.77 |
| hh-clint | Human hepatocyte intrinsic clearance | 27.733 | uL/min/10^6 cells | Moderate | 0.77 |
| hlm-clint | Human liver microsomal intrinsic clearance | 139.959 | uL/min/mg protein | Moderate | 0.77 |
| hppb | Human plasma protein binding (% unbound) | 6.320 | % | Moderate | 0.77 |
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK,TGFBR1 | 21 | |||
| kinase-selectivity-class | AXL,GRK2,MAP2K6 | 3 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 6.339 | Moderate | 0.73 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 4.406 | Moderate | 0.77 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 55.719 | Moderate | 0.77 | |
| mppb | Mouse plasma protein binding (% unbound) | 5.900 | Moderate | 0.77 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 15.453 | Moderate | 0.77 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | Moderate | 0.73 | |
| pppb | Pig plasma protein binding (% unbound) | 13.460 | % | Moderate | 0.77 |
| rat-kpuu-brain | Rat brain Kpuu | 0.058 | % | Moderate | 0.73 |
| rh-clint | Rat hepatocyte intrinsic clearance | 112.202 | uL/min/10^6 cells | Moderate | 0.77 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 43.530 | % | Moderate | 0.77 |
| rppb | Rat plasma protein binding (% unbound) | 5.370 | % | Moderate | 0.77 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 90.782 | uM | Moderate | 0.77 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA MoA | N0000175450 | Corticosteroid Hormone Receptor Agonists |
| FDA EPC | N0000175576 | Corticosteroid |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000932 | Antiemetics |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D005938 | Glucocorticoids |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D018931 | Antineoplastic Agents, Hormonal |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:33231 | antitubercular agent |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35442 | antiparasitic agent |
| CHEBI has role | CHEBI:35472 | anti-inflammatory drug |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:35703 | xenobiotic |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:35718 | antifungal agent |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:35845 | gout suppressant |
| CHEBI has role | CHEBI:37962 | adrenergic agent |
| CHEBI has role | CHEBI:38068 | antimalarial |
| CHEBI has role | CHEBI:39456 | antiglaucoma drug |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:50671 | antithyroid drug |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:50857 | anti-allergic agent |
| CHEBI has role | CHEBI:50919 | antiemetic |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
| CHEBI has role | CHEBI:62868 | hepatoprotective agent |
| CHEBI has role | CHEBI:65023 | anti-asthmatic agent |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:73336 | vulnerary |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:77715 | nasal decongestant |
| CHEBI has role | CHEBI:78298 | environmental contaminant |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.24 | acidic |
| pKa2 | 11.86 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoid receptor | Nuclear hormone receptor | Ki | 8.26 | CHEMBL | |||||
| Mineralocorticoid receptor | Nuclear hormone receptor | IC50 | 7.48 | CHEMBL | |||||
| Androgen receptor | Nuclear hormone receptor | Ki | 5.85 | CHEMBL | |||||
| Progesterone receptor | Nuclear hormone receptor | Ki | 6.25 | CHEMBL | |||||
| Inhibitor of nuclear factor kappa-B kinase subunit beta | Kinase | IC50 | 9.30 | CHEMBL | |||||
| Inhibitor of nuclear factor kappa-B kinase subunit alpha | Kinase | IC50 | 9.30 | CHEMBL | |||||
| Androgen receptor | Transcription factor | IC50 | 4.09 | CHEMBL | |||||
| Fatty acid-binding protein, liver | Cytosolic other | Ki | 4.66 | CHEMBL | |||||
| Progesterone receptor | Transcription factor | IC50 | 4.63 | CHEMBL | |||||
| Glucocorticoid receptor | Transcription factor | IC50 | 7.66 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D01948 | KEGG_DRUG |
| 3264 | RXNORM |
| 4017922 | VANDF |
| C0057590 | UMLSCUI |
| DEX | PDB_CHEM_ID |
| CHEMBL384467 | ChEMBL_ID |
| OI7CP949NN | UNII |
| 63047 | PUBCHEM_CID |
| 4552 | MMSL |
| 6848 | MMSL |
| d00206 | MMSL |
| 002174 | NDDF |
| 372584003 | SNOMEDCT_US |
| 7561000 | SNOMEDCT_US |
| C0011777 | UMLSCUI |
| DB01234 | DRUGBANK_ID |
| 5743 | PUBCHEM_CID |
| 816 | INN_ID |
| D003907 | MESH_DESCRIPTOR_UI |
| CHEBI:41879 | CHEBI |
| OI7CP949NN | INXIGHT DRUGS |
Pharmaceutical products:
None